Sugi Predict

Sugi Predict / Compounds / SCHEMBL1286681

SCHEMBL1286681

SCHEMBL1286681

CC(=O)c1c(Cl)cncc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP7 Q93009 3/20 0.43
▸ MAPT P10636 1/20 0.39
▸ CYP3A4 P08684 2/20 0.38
▸ USP47 Q96K76 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ THRB P10828 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HCAR2 Q8TDS4 1/20 0.35
▸ ICAM1 P05362 1/20 0.35
▸ SELE P16581 1/20 0.35
▸ VCAM1 P19320 1/20 0.35
▸ HDAC3 O15379 1/20 0.35
▸ HDAC4 P56524 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC7 Q8WUI4 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ HDAC10 Q969S8 1/20 0.35
▸ HDAC11 Q96DB2 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29793559 0.87 CYP3A4 (0.40) USP7MAPTCYP3A4USP47MEN1
SCHEMBL18571885 0.87 CYP3A4 (0.40) USP7MAPTCYP3A4USP47MEN1
SCHEMBL23111961 0.85 USP7 (0.38) USP7MAPTCYP3A4USP47
SCHEMBL30765119 0.85 USP7 (0.38) USP7MAPTCYP3A4USP47
SCHEMBL30765126 0.85 USP7 (0.38) USP7MAPTCYP3A4USP47
SCHEMBL111872 0.77 HCAR2 (0.46) MAPTCYP3A4MEN1KMT2AHCAR2
SCHEMBL1666884 0.77 ALDH1A1 (0.54) USP7MAPTCYP3A4HCAR2ICAM1
SCHEMBL18572342 0.75 PDE4D (0.36) USP7PDE4D
SCHEMBL1703067 0.75 ICAM1 (0.47) MAPTCYP3A4HCAR2ICAM1SELE
SCHEMBL5261080 0.75 CYP3A4 (0.38) USP7MAPTCYP3A4HCAR2ICAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111705099-B Preparation method of (S) -1- (3, 5-dichloropyridine-4-substituted) ethanol 天津药明康德新药开发有限公司 2022-03-08 — — CN claimed
US-20030013713-A1 Compounds as PDE IV and TNF-inhibitors FENTON GARRY (GB) 2003-01-16 — — US claimed
CN-121046339-A Ketone reductase mutant and application thereof in preparation of (S) -1- (3, 5-dichloropyridine-4-substituted) ethanol 尚科生物医药（上海）有限公司 2025-12-02 — — CN disclosed
CN-121046338-A Ketone reductase mutant and application thereof in preparation of (R) -1- (3, 5-dichloropyridine-4-substituted) ethanol 尚科生物医药（上海）有限公司 2025-12-02 — — CN disclosed
CN-111705099-B Preparation method of (S) -1- (3, 5-dichloropyridine-4-substituted) ethanol 天津药明康德新药开发有限公司 2022-03-08 — — CN disclosed
CN-111705099-B Preparation method of (S) -1- (3, 5-dichloropyridine-4-substituted) ethanol 天津药明康德新药开发有限公司 2022-03-08 — — CN disclosed
EP-2865446-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL KANTO KAGAKU (JP) 2021-09-22 — — EP disclosed
US-9174906-B2 Process for producing optically active secondary alcohol KANTO KAGAKU KABUSHIKI KAISHA (JP) 2015-11-03 — — US disclosed
EP-1845973-B1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LTD (GB) 2015-08-12 — — EP disclosed
US-9051278-B2 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators ASTEX THERAPEUTICS, LTD. (GB) 2015-06-09 — — US disclosed
US-9051278-B2 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators ASTEX THERAPEUTICS, LTD. (GB) 2015-06-09 — — US disclosed
US-7385059-B2 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections ASTEX THERAPEUTICS LIMITED (GB) 2008-06-10 — — US disclosed
US-7385059-B2 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections ASTEX THERAPEUTICS LIMITED (GB) 2008-06-10 — — US disclosed
WO-2008007123-A2 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2008-01-17 — — WO disclosed
WO-2006077424-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2006077428-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2006077419-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2006077414-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2006077425-A1 COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 — — WO disclosed
WO-2005012256-A1 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013713-A1 Compounds as PDE IV and TNF-inhibitors PDE4A, PDE4B, PDE7A USP7 2762/4885MAPT 4353/4885CYP3A4 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.